Search Within

Ellin Berman

  1. "2019"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (2)
  3. Correspondence (1)
Groups
  1. Adult Leukemia (9)
  2. Center for Hematologic Malignancies (9)
  3. Department of Medicine (9)
  4. Hematologic Malignancies, Division of (9)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (2)
  6. Executive Committee, Center for Hematologic Malignancies (2)

More Groups

People
  1. Christopher Famulare (2)
  2. Ross Levine (2)
Years
  1. 2019 (9)
Publications
  1. Blood (2)
  2. Journal of Clinical Oncology (2)
  3. Cancer Research (1)
  4. Haematologica (1)
  5. New England Journal of Medicine (1)
  6. Oncology Research and Treatment (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (2)
  2. American Society of Hematology (2)
  3. American Association for Cancer Research (1)
  4. American Association for the Advancement of Science (1)
  5. Ferrata Storti Foundation (1)
  6. Massachusetts Medical Society (1)

More Publishers

Results (9)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Overcoming adaptive therapy resistance in AML by targeting immune response pathways
    Meeting Abstract

    Melgar, K. M.; Jones, L. M.; Walker, M.; Bolanos, L. C.; Hueneman, K.; Wunderlich, M.; Jiang, J. K.; Wilson, K.; Zhang, X.; Sutter, P.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: Results from the phase 3 ADMIRAL trial
    Meeting Abstract

    Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; more...
    Oncology Research and Treatment (2019)

    Fulltext@MSK | Save
  • Emerging mutations at relapse in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia who received gilteritinib therapy in the phase 3 ADMIRAL trial
    Meeting Abstract

    Smith, C. C.; Levis, M. J.; Perl, A. E.; Martinelli, G.; Neubauer, A.; Berman, E.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Chou, W. C.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: Results from the phase 3 admiral trial
    Meeting Abstract

    Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; more...
    Haematologica (2019)

    Fulltext@MSK | Save
  • Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML
    Journal Article

    Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; more...
    New England Journal of Medicine (2019)

    Fulltext@MSK | Save
  • Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio
    Meeting Abstract

    Levis, M. J.; Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Chou, W. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3(mut+)) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the phase III ADMIRAL trial
    Meeting Abstract

    Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Overcoming adaptive therapy resistance in AML by targeting immune response pathways
    Journal Article

    Melgar, K.; Walker, M. M.; Jones, L. M.; Bolanos, L. C.; Hueneman, K.; Wunderlich, M.; Jiang, J. K.; Wilson, K. M.; Zhang, X.; Sutter, P.; more...
    Science Translational Medicine (2019)

    Fulltext@MSK | Save
  • Reply to N. Cerveira et al
    Correspondence

    Berman, E.; Druker, B. J.; Burwick, R.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save